A Novel Conditional Adra2a-Knockout Mouse Line Reveals Cell-specific Contributions to Specific Dimensions of Sedation
Noah L FryouiD, Timothy Jiang, Nathan Frick, Paula Kwasniewska, Mikhail Y. LipiniD, Max B. KelziD, STEVEN A. THOMAS, Andrew R. McKinstry-WuiD
Abstract
IntroductionHere, we create a conditional Adra2a line and use it to show that sedative, hypnotic, and hypothermic effects of 2-agonists are neuronally mediated via the 2A adrenergic receptor. MethodsWe generated mice with loxP sites flanking Adra2a using CRISPR/Cas9 gene targeting. This line was crossed with lines encoding Cre recombinase (Cre) under the control of the Vgat, Snap25, and Dbh promoters. Cell-specific knockout was confirmed using fluorescent in-situ hybridization demonstrating targeted reduction in Adra2a mRNA in the appropriate cell types. Mice were given intraperitoneal dexmedetomidine (0.3 or 1 mg/kg) or saline, and 20 minutes later righting reflex was assessed, followed by 3 rounds of rotarod testing, with fall time and end temperature recorded. Spontaneous activity was recorded using beam break for an hour after. Mice of each genotype were implanted with EEG leads and recorded while given 0.3 mg/kg IP dexmedetomidine. ResultsWe created a conditional knockout and demonstrated cell-type specific reduction of Adra2a mRNA in crossed lines with cell-specific Cre. The pan-neuronal Adra2a knockout showed resistance to all temperature, sedative, and hypnotic effect endpoints in response to the 2-agonist dexmedetomidine. Adrenergic knockout demonstrated resistance to 2-agonist hypnosis and moderate resistance to hypothermia and impaired coordination with forced movement. GABAergic knockout showed resistance only to impairment of spontaneous movement by 2-agonists. Spectral analysis of the EEG showed an increase in proportion of delta power with a sedative dose of dexmedetomidine in all lines except the pan-neuronal Adra2a knockout. DiscussionFuture studies will pursue both the specific subtype(s) and location of neuronal populations responsible for sedative, hypnotic, and hypothermic effects of 2-agonists.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neural signatures of α2 adrenergic agonist-induced unconsciousness and awakening by antagonist
J. J. Ballesteros, Jessica Briscoe, Yumiko Ishizawa·eLifePeer-reviewed·Aug 28, 2020
- Knock-in rat lines with Cre recombinase at the dopamine D1 and adenosine 2a receptor loci.
Jeffrey R. Pettibone, Jai Y. Yu, … Joshua D. Berke·eNeuroPeer-reviewed·Aug 26, 2019
- Inhibition of noradrenaline-dependent synaptic transmission in the dorsal raphe nucleus by alpha2-adrenergic receptors
Aleigha Gugel, Erik A. Ingebretsen, … Stephanie C. Gantz·NeuropsychopharmacologyPeer-reviewed·Feb 17, 2024
- Xylazine's k-opioid agonist activity is not shared with other FDA-approved alpha2-adrenergic agonists
Xi-Ping Huang, Brian E Krumm, … Bryan L. Roth·bioRxiv·Mar 7, 2026
- Loss of β-arrestin2 in D2 cells alters neuronal excitability in the nucleus accumbens and behavioral responses to psychostimulants and opioids
Kirsten A. Porter‐Stransky, Alyssa K. Petko, … David Weinshenker·Addiction BiologyPeer-reviewed·Aug 23, 2019
- Distinct roles of general anesthesia activated CeA neurons in acute versus late phase of neuropathic pain
Junli Zhao, Kenta Furutani, … Ru‐Rong Ji·bioRxiv·Sep 11, 2024